Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene

Movement Disorders

Volumn 30, Issue 7, 2015, Pages 981-986

  Mirelman, Anat ^a   Alcalay, Roy N ^b,c   Saunders Pullman, Rachel ^d,e   Yasinovsky, Kira ^a   Thaler, Avner ^a   Gurevich, Tanya ^a,f   Mejia Santana, Helen ^b   Raymond, Deborah ^d   Gana Weisz, Mali ^a   Bar Shira, Anat ^a   Ozelius, Laurie ^e   Clark, Lorraine ^b   Orr Urtreger, Avi ^a,f   Bressman, Susan ^d,e   Marder, Karen ^b,c   Giladi, Nir ^a,f  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b Columbia University ^*  (United States)

^c Department of Medicine   (United States)

^d BETH ISRAEL MEDICAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f TEL AVIV UNIVERSITY   (Israel)

Author keywords

LRRK2; Non manifesting carriers; Parkinson's disease; Prodromal

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; ANXIETY; ARTICLE; ASHKENAZI JEW; ATTENTION; COGNITION; CONSTIPATION; CROSS-SECTIONAL STUDY; DAYTIME SOMNOLENCE; DEPRESSION; EXECUTIVE FUNCTION; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GERIATRIC DEPRESSION SCALE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; OBSERVATIONAL STUDY; ODOR; PARKINSON DISEASE; PRIORITY JOURNAL; PRODROMAL SYMPTOM; REM SLEEP; SLEEP; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY URGENCY; GENETICS; JEW; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HETEROZYGOTE; HUMANS; JEWS; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PRODROMAL SYMPTOMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84931840827     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26213     Document Type: Article

References (30)

1. Evans JR, Mason SL, William-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112-1118.
2. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology 2007;69:1595-1602.
3. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006;354:424-425.
4. Goldwurm S, Zini M, Mariani L, et al. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease. Neurology 2007;68:1141-1143.
5. Age Specific Penetrance of the LRRK2 G2019S mutation in the Michael J Fox Ashkenazi Jewish (AJ) LRRK2 Consortium. World Parkinson Conference: 2013.
6. Saunders-Pullman R, Stanley K, Wang C, et al. Olfactory dysfunction in LRRK2 G2019S mutation carriers. Neurology 2011;77:319-324.
7. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011;69:193-197.
8. Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 2012;79:1027-1032.
9. Fahn S, Elton R, Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Health Care Information; 1987:153-163.
10. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
11. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire: a new diagnostic instrument. Mov Disord 2007;22:2386-2393.
12. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
13. Franzen MD, Tishelman AC, Sharp BH, Friedman AG. An investigation of the test-retest reliability of the Stroop Color-Word Test across two intervals. Arch Clin Neuropsychol 1987;2:265-272.
14. Sanchez-Cubillo I, Perianez JA, Adrover-Roig D, Rodriguez-Sanchez JM, Rios-Lago M, Tirapu J, Barceló F. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. J Int Neuropsychol Soc 2009;15:438-450.
15. Alcalay RN, Mejia-Santana H, Mirelman A, et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism Relat Disord 2015;21:106-110.
16. Meara J, Mitchelmore E, Hubson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999;28:35-38.
17. Mondolo F, Jahanshahi M, Grana A, Biasutti E, Cacciatori E, Di BP. Evaluation of anxiety in Parkinson's disease with some commonly used rating scales. Neurol Sci 2007;28:270-275.
18. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008;23:2015-2025.
19. Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY. Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 2008;447:12-16.
20. Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 2007;254:84-90.
21. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010;32:775-779.
22. Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010;25:2105-2013.
23. Yamanishi T, Tachibana J, Oguru M, Matsui K, Toda K, Okuda B, Oka N. Anxiety and depression in patients with Parkinson's disease. Intern Med 2013;52:539-545.
24. Thaler A, Mirelman A, Helmich RC, et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 2013;49:2501-2511.
25. Thaler A, Artzi M, Mirelman A, et al. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. Mov Disord 2014;29:823-827.
26. van Nuenen BF, Helmich RC, Ferraye M, et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012;135:3687-3698.
27. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617-626.
28. Gaig C, Vilas D, Infante J, et al. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease. PLoS One 2014;9:e108982.
29. Meissner WG. When does Parkinson's disease begin? From prodromal disease to motor signs. Rev Neurol (Paris) 2012;168:809-814.
30. Postuma RB, Gagnon JF, Pelletier A, Motplaisir J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013;28:597-604.